V-Go meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy to use. V-Go mimics the insulin pattern of the body (when used according to the ...

CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced that Brenzavvy™ (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, is now available by ...

The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies ...

Senseonics plans to take back full commercial control of its Eversense continuous glucose monitoring platforms from its distribution partner Ascensia Diabetes Care, as it aims to speed up the rollout ...

Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity--announced that Mr. Jesper Høiland has been ...

China’s Hua Medicine has spent over a decade on one medicine—a diabetes candidate in-licensed from Roche. Now under a partnership with Bayer, the drug has snagged a global first-in-class nod in China.

The daily pill may provide a more convenient alternative to injections, which patients can find difficult to administer.